AGIOS PHARMACEUTICALS, INC.AGIOEarnings & Financial Report
Agios Pharmaceuticals Inc. is a publicly trading American pharmaceutical company pioneering therapies for genetically defined diseases, with a near-term focus on developing therapies for hemolytic anemias. The company was founded in 2008 by Lewis Cantley, Tak Mak and Craig Thompson. Agios is a Delaware corporation headquartered in Cambridge, Massachusetts. The company tendered an initial public offering in July 2013.
Revenue
$8.7M
Gross Profit
$7.6M
Operating Profit
$-106.6M
Net Profit
$-89.3M
Gross Margin
87.6%
Operating Margin
-1222.0%
Net Margin
-1023.3%
YoY Growth
6.6%
EPS
$-1.55
AGIOS PHARMACEUTICALS, INC. Q1 FY2025 Financial Summary
AGIOS PHARMACEUTICALS, INC. reported revenue of $8.7M (up 6.6% YoY) for Q1 FY2025, with a net profit of $-89.3M (down 9.5% YoY) (-1023.3% margin). Cost of goods sold was $1.1M, operating expenses totaled $114.3M.
Key Financial Metrics
| Total Revenue | $8.7M |
|---|---|
| Net Profit | $-89.3M |
| Gross Margin | 87.6% |
| Operating Margin | -1222.0% |
| Report Period | Q1 FY2025 |
AGIOS PHARMACEUTICALS, INC. Annual Revenue by Year
AGIOS PHARMACEUTICALS, INC. annual revenue history includes year-by-year totals (for example, 2025 revenue was $54.0M).
| Year | Annual Revenue |
|---|---|
| 2025 | $54.0M |
| 2024 | $36.5M |
| 2023 | $26.8M |
| 2022 | $14.2M |
AGIOS PHARMACEUTICALS, INC. Quarterly Revenue & Net Profit History
AGIOS PHARMACEUTICALS, INC. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $20.0M | +86.1% | $-108.0M | -541.1% |
| Q3 FY2025 | $12.9M | +43.7% | $-103.4M | -803.1% |
| Q2 FY2025 | $12.5M | +44.6% | $-112.0M | -899.4% |
| Q1 FY2025 | $8.7M | +6.6% | $-89.3M | -1023.3% |
| Q4 FY2024 | $10.7M | +51.1% | $-96.5M | -899.6% |
| Q3 FY2024 | $9.0M | +21.2% | $947.9M | 10574.7% |
| Q2 FY2024 | $8.6M | +28.4% | $-96.1M | -1115.7% |
| Q1 FY2024 | $8.2M | +46.0% | $-81.5M | -995.8% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $8.2M | $8.6M | $9.0M | $10.7M | $8.7M | $12.5M | $12.9M | $20.0M |
| YoY Growth | 46.0% | 28.4% | 21.2% | 51.1% | 6.6% | 44.6% | 43.7% | 86.1% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $849.7M | $773.1M | $1.79B | $1.66B | $1.56B | $1.47B | $1.39B | $1.30B |
| Liabilities | $105.8M | $112.6M | $165.1M | $122.2M | $89.0M | $101.7M | $101.4M | $104.1M |
| Equity | $743.9M | $660.5M | $1.63B | $1.54B | $1.47B | $1.37B | $1.28B | $1.19B |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-99.9M | $-72.6M | $-84.2M | $-133.2M | $-111.5M | $-77.1M | $-88.2M | $-96.2M |